Hoffmann-La Roche Inc.

Health Research, Inc.

F. Hoffmann-La Roche Ag

Brigitte Schott

Bernd Kuhn

Wolfgang Haap

Paul Hebeisen

Eric Argirios Kitas

Hans Peter Wessel

Marcel Gubler

Rudolf E Minder

Eugene Kandel

Evan Zynda

Provided are compositions and methods for inhibiting hypoxia-induced damage. The compositions and methods involve the use of one or more agents that can inhibit one or any combination of the genes BCL2L14, BLOC1S2, C20RF42, CPT1A, FBP1, GCNT3, RHOB, SCIN, TACR1 and TNFAIP6. Polynucleotide and non-polynucleotide agents which can be used for inhibiting one or more of the genes are included. The method involves introducing one or more gene inhibiting agents to a cell, tissue, organ, or individual such that formation of hypoxia related damage is inhibited. Kits which contain the agents and printed information about using them for inhibiting hypoxia induced damage are also included.

Compositions and methods for inhibiting hypdxia induced damage

Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein Rto Rhave the significance given in the application and which can be used in the form of pharmaceutical compositions.

FBPase inhibitors for diabetes

Growing community of inventors

Landser, France

Brigitte Schott